Literature DB >> 27146154

Angiopoietin 2 expression in the cornea and its control of corneal neovascularisation.

Giulio Ferrari1,2, Chiara Giacomini1, Fabio Bignami1, Davide Moi3,4, Anna Ranghetti3, Claudio Doglioni5, Luigi Naldini3,5, Paolo Rama1,2, Roberta Mazzieri3,4.   

Abstract

PURPOSE: To define proangiogenic angiopoietin 2 (ANG2) expression and role(s) in human and mouse vascularised corneas. Further, to evaluate the effect of ANG2 inhibition on corneal neovascularisation (CNV).
METHODS: CNV was induced in FVB mice by means of intrastromal suture placement. One group of animals was sacrificed 10 days later; corneas were immunostained for ANG2 and compared with (i) mouse non-vascularised corneas and (ii) human vascularised and non-vascularised corneas. A second group of CNV animals was treated systemically with an anti-ANG2 antibody. After 10 days, the corneas were whole-mounted, stained for CD31 and LYVE1 and lymphatic/blood vessels quantified. In another set of experiments, the corneal basal Bowman membrane was either (i) removed or (ii) left in place. After 2 or 10 days the corneas were removed and immunostained for collagen IV, ANG2, CD31, LYVE1, CD11b and MRC1 markers.
RESULTS: In human beings and mice, ANG2 is expressed only in the epithelium, and, mildly, in the endothelium, of the avascular cornea. Instead, it is expressed in the epithelium, endothelium and stroma of vascularised corneas. Disruption of the Bowman membrane is associated with a significant increase of (i) ANG2 stromal expression and (ii) proangiogenic macrophage infiltration in the corneal stroma. Finally, blocking ANG2 significantly reduced hemangiogenesis, lymphangiogenesis and macrophage infiltration.
CONCLUSIONS: Balancing proper healing and good vision is crucial in the cornea, constantly exposed to potential injuries. In this paper, we suggest the existence of a mechanism regulating the onset of inflammation (and associated CNV) depending on injury severity. Published by the BMJ Publishing Group Limited. For permission to use (where not already granted under a licence) please go to http://www.bmj.com/company/products-services/rights-and-licensing/.

Entities:  

Keywords:  Angiogenesis; Cornea; Inflammation; Neovascularisation; Ocular surface

Mesh:

Substances:

Year:  2016        PMID: 27146154     DOI: 10.1136/bjophthalmol-2015-307901

Source DB:  PubMed          Journal:  Br J Ophthalmol        ISSN: 0007-1161            Impact factor:   4.638


  3 in total

Review 1.  Animal models of ocular angiogenesis: from development to pathologies.

Authors:  Chi-Hsiu Liu; Zhongxiao Wang; Ye Sun; Jing Chen
Journal:  FASEB J       Date:  2017-07-24       Impact factor: 5.191

2.  Angiopoietin-2 Blockade Promotes Survival of Corneal Transplants.

Authors:  Liwei Zhang; Guangyu Li; Roberto Sessa; Gyeong Jin Kang; Meng Shi; Shaokui Ge; Anna Jiang Gong; Ying Wen; Sudhakar Chintharlapalli; Lu Chen
Journal:  Invest Ophthalmol Vis Sci       Date:  2017-01-01       Impact factor: 4.799

Review 3.  Variable Responses to Corneal Grafts: Insights from Immunology and Systems Biology.

Authors:  Antonio Di Zazzo; Sang-Mok Lee; Jaemyoung Sung; Matteo Niutta; Marco Coassin; Alireza Mashaghi; Takenori Inomata
Journal:  J Clin Med       Date:  2020-02-21       Impact factor: 4.241

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.